X.u

Multiple organ dysfunction/failure (MODS/MOF)

Last update : 17/05/2014
 

Causative drugs

30

Abused drugs/substances (illicit-, street drugs - IV/inhaled)

I.j I - Interstitial/parenchymal lung disease
I.j - Exogenous lipoid pneumonia
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.s I - Interstitial/parenchymal lung disease
I.s - A mass or masses
I.t I - Interstitial/parenchymal lung disease
I.t - Pneumoconiosis, talcosis
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
IV.f IV - Airway involvement
IV.f - Severe, catastrophic asthma attack (can be fatal)
IV.g IV - Airway involvement
IV.g - Syncope - Cough syncope
V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax
V.q V - Pleural and/or pericardial involvement
V.q - Empyema
VI.b VI - Pulmonary vasculopathy
VI.b - Pulmonary arterial hypertension
VI.c VI - Pulmonary vasculopathy
VI.c - Pulmonary veno-occlusive disease
VI.g VI - Pulmonary vasculopathy
VI.g - Foreign body vasculopathy (Excipient lung disease)
VI.i VI - Pulmonary vasculopathy
VI.i - Acute pulmonary hypertension
VI.j VI - Pulmonary vasculopathy
VI.j - Mercury pulmonary embolism
VI.r VI - Pulmonary vasculopathy
VI.r - Septic pulmonary embolism
VI.t VI - Pulmonary vasculopathy
VI.t - Pulmonary artery aneurysm(s)
VII.h VII - Mediastinal involvement
VII.h - Pneumomediastinum
VIII.c VIII - Upper, central, large airway involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma
VIII.d VIII - Upper, central, large airway involvement
VIII.d - Thermal (burns, frostbite), chemical, or caustic facial and/or airway injury
IX.a IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.a - Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)
IX.s IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.s - Botulism - Wound botulism
X.u X - Systemic conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
X.ac X - Systemic conditions, syndromes and reactions
X.ac - Anti-GBM antibody disease (Goodpasture-like) or flare of
XI.b XI - Miscellaneous
XI.b - Chest pain (acute - subacute)
XI.g XI - Miscellaneous
XI.g - Aspiration, aspiration pneumonia (w/wo demonstrable pharyngeal dysmotility)
XI.m XI - Miscellaneous
XI.m - Pulmonary emphysema - Lung cysts or bullae
XI.r XI - Miscellaneous
XI.r - Death following exposure or poisoning
XII.i XII - Cardiovascular involvement / toxicity
XII.i - Endocarditis (infective)
XII.v XII - Cardiovascular involvement / toxicity
XII.v - Hypertrophic cardiomyopathy
XV.q XV - Pulmonary pathology
XV.q - Path: Foreign body deposits/reaction
XV.s XV - Pulmonary pathology
XV.s - Path: Pneumoconiosis (silicosis, talcosis, talcoma)
XV.ag XV - Pulmonary pathology
XV.ag - Path: Foreign body embolism, microangiopathy, vasculopathy
XV.al XV - Pulmonary pathology
XV.al - Path: Pulmonary hypertension incl. angiomatoid vasculopathy
XVI.v XVI - Imaging
XVI.v - Imaging: Diffuse centrilobular micronodules
XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating lung nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)
XVI.ae XVI - Imaging
XVI.ae - Imaging: A pattern similar to progressive massive fibrosis (PMF)
XVI.af XVI - Imaging
XVI.af - Imaging: Lung cysts or bullae (see also XVI ah/bf)
XVII.a XVII - Infections & related conditions
XVII.a - Pneumonia - Respiratory tract infection
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
XVII.p XVII - Infections & related conditions
XVII.p - Lung abscess/abscesses (see also VIr)
XVII.s XVII - Infections & related conditions
XVII.s - Sternoclavicular septic arthritis
XVII.u XVII - Infections & related conditions
XVII.u - Epidural abscess
1

Aspirin (Salicylate-ASA)

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
III.c III - Pulmonary hemorrhage
III.c - Hemoptysis
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
IV.f IV - Airway involvement
IV.f - Severe, catastrophic asthma attack (can be fatal)
V.e V - Pleural and/or pericardial involvement
V.e - Hemothorax - Serosanguineous pleural effusion
VII.b VII - Mediastinal involvement
VII.b - Lymphadenopathy with reactive changes
VIII.a VIII - Upper, central, large airway involvement
VIII.a - Angioedema (may cause UAO & asphyxia)
VIII.y VIII - Upper, central, large airway involvement
VIII.y - Sinonasal discharge, -blockage, -obstruction
X.a X - Systemic conditions, syndromes and reactions
X.a - DRESS (drug rash eosinophilia and hypersensitivity syndrome)
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
X.h X - Systemic conditions, syndromes and reactions
X.h - Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
X.m X - Systemic conditions, syndromes and reactions
X.m - Pulmonary and/or systemic vasculitis (ANCA status MPO, unknown or negative)
X.q X - Systemic conditions, syndromes and reactions
X.q - Systemic inflammatory response
X.u X - Systemic conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
XI.b XI - Miscellaneous
XI.b - Chest pain (acute - subacute)
XI.d XI - Miscellaneous
XI.d - Metabolic acidosis (incl. lactic-). May cause dyspnea
XII.n XII - Cardiovascular involvement / toxicity
XII.n - Hypotension, shock, cardiovascular collapse
XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-)
XII.af XII - Cardiovascular involvement / toxicity
XII.af - Coronary arterial spasm
1

BCG therapy (topical, via bladder instillations)

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
IV.d IV - Airway involvement
IV.d - Cough (lone)
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic)
VII.e VII - Mediastinal involvement
VII.e - Granulomatous mediastinal lymphadenopathy
VIII.c VIII - Upper, central, large airway involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma
IX.r IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.r - Myasthenia gravis (may cause neuromuscular ARF)
X.g X - Systemic conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways)
X.l X - Systemic conditions, syndromes and reactions
X.l - Systemic granulomatosis other than Xk
X.m X - Systemic conditions, syndromes and reactions
X.m - Pulmonary and/or systemic vasculitis (ANCA status MPO, unknown or negative)
X.u X - Systemic conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
XV.e XV - Pulmonary pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XV.f XV - Pulmonary pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XVI.u XVI - Imaging
XVI.u - Imaging: A miliary pattern (diffuse random micronodules)
XVII.f XVII - Infections & related conditions
XVII.f - Tuberculosis, miliary
XVII.i XVII - Infections & related conditions
XVII.i - M. bovis (BCG) infection (topical - systemic)
1

Chemicals

I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.j I - Interstitial/parenchymal lung disease
I.j - Exogenous lipoid pneumonia
I.af I - Interstitial/parenchymal lung disease
I.af - Chemical pneumonitis
II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
III.b III - Pulmonary hemorrhage
III.b - Pneumorenal syndrome
IV.c IV - Airway involvement
IV.c - Obliterative bronchiolitis (see also IVn)
IV.n IV - Airway involvement
IV.n - Obstructive airway dysfunction (see also IVc)
IV.q IV - Airway involvement
IV.q - Reactive airway dysfunction syndrome (RADS)
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
VIII.c VIII - Upper, central, large airway involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma
VIII.h VIII - Upper, central, large airway involvement
VIII.h - Vocal cord dysfunction, adduction, closure
X.m X - Systemic conditions, syndromes and reactions
X.m - Pulmonary and/or systemic vasculitis (ANCA status MPO, unknown or negative)
X.u X - Systemic conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
X.ac X - Systemic conditions, syndromes and reactions
X.ac - Anti-GBM antibody disease (Goodpasture-like) or flare of
XI.s XI - Miscellaneous
XI.s - Death following inhalation of compound - Sniffing death
XII.m XII - Cardiovascular involvement / toxicity
XII.m - Cardiac/cardiopulmonary arrest
XIV.a XIV - Hemoglobinopathies-Abnormal hemoglobins states (acquired)
XIV.a - Methemoglobinemia
XIV.b XIV - Hemoglobinopathies-Abnormal hemoglobins states (acquired)
XIV.b - Sulfhemoglobinemia
XV.x XV - Pulmonary pathology
XV.x - Path: Acute or subacute bronchiolitis (see also IVc, IVi)
XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating lung nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)
XVII.p XVII - Infections & related conditions
XVII.p - Lung abscess/abscesses (see also VIr)
1

Cocaine

I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP)
II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.d II - Pulmonary edema - ARDS - Acute respiratory failure
II.d - Pulmonary edema, cardiogenic
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
III.b III - Pulmonary hemorrhage
III.b - Pneumorenal syndrome
III.c III - Pulmonary hemorrhage
III.c - Hemoptysis
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
IV.f IV - Airway involvement
IV.f - Severe, catastrophic asthma attack (can be fatal)
IV.o IV - Airway involvement
IV.o - Airway hyperresponsiveness
V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax
VI.a VI - Pulmonary vasculopathy
VI.a - Pulmonary embolism - Venous thromboembolism
VI.b VI - Pulmonary vasculopathy
VI.b - Pulmonary arterial hypertension
VI.l VI - Pulmonary vasculopathy
VI.l - Acute pulmonary vasoconstriction and PHT
VII.h VII - Mediastinal involvement
VII.h - Pneumomediastinum
VIII.a VIII - Upper, central, large airway involvement
VIII.a - Angioedema (may cause UAO & asphyxia)
VIII.c VIII - Upper, central, large airway involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma
VIII.i VIII - Upper, central, large airway involvement
VIII.i - Midline destructive lesions
VIII.w VIII - Upper, central, large airway involvement
VIII.w - Uvulitis, uvular edema
IX.k IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.k - Trismus (lockjaw)
IX.o IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.o - Pneumorachis
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
X.j X - Systemic conditions, syndromes and reactions
X.j - Myositis/polymyositis/DPM/rhabdomyolysis/myopathy
X.m X - Systemic conditions, syndromes and reactions
X.m - Pulmonary and/or systemic vasculitis (ANCA status MPO, unknown or negative)
X.o X - Systemic conditions, syndromes and reactions
X.o - Neutrophilic dermatosis (Pyoderma, Sweet)
X.s X - Systemic conditions, syndromes and reactions
X.s - Pulmonary/systemic vasculitis/polyangiitis (ANCA-positive)
X.u X - Systemic conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
X.x X - Systemic conditions, syndromes and reactions
X.x - Subclinical ANCA positivity
X.ac X - Systemic conditions, syndromes and reactions
X.ac - Anti-GBM antibody disease (Goodpasture-like) or flare of
X.ad X - Systemic conditions, syndromes and reactions
X.ad - Skin purpura, ecchymoses or necrosis
X.as X - Systemic conditions, syndromes and reactions
X.as - Scleroderma renal crisis
XI.b XI - Miscellaneous
XI.b - Chest pain (acute - subacute)
XI.m XI - Miscellaneous
XI.m - Pulmonary emphysema - Lung cysts or bullae
XI.n XI - Miscellaneous
XI.n - Neutropenia, agranulocytosis (w/wo infection/sepsis)
XI.r XI - Miscellaneous
XI.r - Death following exposure or poisoning
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left ventricular dysfunction/failure
XII.e XII - Cardiovascular involvement / toxicity
XII.e - Takotsubo (stress) cardiomyopathy
XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic)
XII.g XII - Cardiovascular involvement / toxicity
XII.g - Myocardial ischemia, coronary artery disease, myocardial infarction
XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
XII.y XII - Cardiovascular involvement / toxicity
XII.y - Pneumopericardium
XII.ae XII - Cardiovascular involvement / toxicity
XII.ae - Aortic dissection
XII.af XII - Cardiovascular involvement / toxicity
XII.af - Coronary arterial spasm
XII.aj XII - Cardiovascular involvement / toxicity
XII.aj - Systemic arterial thrombosis
XII.ap XII - Cardiovascular involvement / toxicity
XII.ap - Coronary artery dissection
XIV.c XIV - Hemoglobinopathies-Abnormal hemoglobins states (acquired)
XIV.c - Carboxyhemoglobinemia
XV.b XV - Pulmonary pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)
XV.g XV - Pulmonary pathology
XV.g - Path: Alveolar hemorrhage (see also IIIa)
XV.h XV - Pulmonary pathology
XV.h - Path: Fibrotic NSIP pattern
XV.w XV - Pulmonary pathology
XV.w - Path: Pulmonary edema (see also II/IIa)
XV.aw XV - Pulmonary pathology
XV.aw - Path: Skin vasculopathy/vasculitis
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
1

Excipients - Vehicle - Preservatives

I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.t I - Interstitial/parenchymal lung disease
I.t - Pneumoconiosis, talcosis
II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
IV.f IV - Airway involvement
IV.f - Severe, catastrophic asthma attack (can be fatal)
IV.i IV - Airway involvement
IV.i - Foreign body aspiration bronchiolitis
VI.b VI - Pulmonary vasculopathy
VI.b - Pulmonary arterial hypertension
VI.e VI - Pulmonary vasculopathy
VI.e - Fat/oil embolism
VI.g VI - Pulmonary vasculopathy
VI.g - Foreign body vasculopathy (Excipient lung disease)
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
X.g X - Systemic conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways)
X.u X - Systemic conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
XI.d XI - Miscellaneous
XI.d - Metabolic acidosis (incl. lactic-). May cause dyspnea
XII.n XII - Cardiovascular involvement / toxicity
XII.n - Hypotension, shock, cardiovascular collapse
XV.q XV - Pulmonary pathology
XV.q - Path: Foreign body deposits/reaction
XV.ae XV - Pulmonary pathology
XV.ae - Path: Lipid/fat embolism (see also VIe)
XVI.q XVI - Imaging
XVI.q - Imaging: A pattern similar/consistent to/with IPF
XVI.v XVI - Imaging
XVI.v - Imaging: Diffuse centrilobular micronodules
1

Herbals - Dietary, botanical therapy - Food

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
II.q II - Pulmonary edema - ARDS - Acute respiratory failure
II.q - Respiratory distress
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
IV.c IV - Airway involvement
IV.c - Obliterative bronchiolitis (see also IVn)
VI.a VI - Pulmonary vasculopathy
VI.a - Pulmonary embolism - Venous thromboembolism
VI.b VI - Pulmonary vasculopathy
VI.b - Pulmonary arterial hypertension
VIII.c VIII - Upper, central, large airway involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma
VIII.w VIII - Upper, central, large airway involvement
VIII.w - Uvulitis, uvular edema
IX.a IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.a - Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)
IX.d IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.d - Ventilatory depression-Hypoventilation (may cause ARF). See also XIe
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
X.u X - Systemic conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
XI.b XI - Miscellaneous
XI.b - Chest pain (acute - subacute)
XI.r XI - Miscellaneous
XI.r - Death following exposure or poisoning
XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis
XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic)
XII.h XII - Cardiovascular involvement / toxicity
XII.h - Eosinophilic myocarditis
XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
XII.m XII - Cardiovascular involvement / toxicity
XII.m - Cardiac/cardiopulmonary arrest
XII.n XII - Cardiovascular involvement / toxicity
XII.n - Hypotension, shock, cardiovascular collapse
XII.w XII - Cardiovascular involvement / toxicity
XII.w - Asystole
XII.ah XII - Cardiovascular involvement / toxicity
XII.ah - Tachycardia
XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - Cardiotoxicity
XV.z XV - Pulmonary pathology
XV.z - Path: Chronic obliterative broncholitis (see also IVc, IVn)
1

Interferon alpha/beta

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.v I - Interstitial/parenchymal lung disease
I.v - Subclinical changes in lung function/PFT
I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
IV.d IV - Airway involvement
IV.d - Cough (lone)
IV.w IV - Airway involvement
IV.w - Plugs/casts in the airways
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
VI.b VI - Pulmonary vasculopathy
VI.b - Pulmonary arterial hypertension
VI.d VI - Pulmonary vasculopathy
VI.d - Pulmonary vasculitis or capillaritis
VI.f VI - Pulmonary vasculopathy
VI.f - The hemolytic and uremic syndrome (HUS). See also under Xaf
VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic)
VII.e VII - Mediastinal involvement
VII.e - Granulomatous mediastinal lymphadenopathy
VIII.a VIII - Upper, central, large airway involvement
VIII.a - Angioedema (may cause UAO & asphyxia)
X.b X - Systemic conditions, syndromes and reactions
X.b - Antiphospholipid antibodies w/wo the APL syndrome
X.c X - Systemic conditions, syndromes and reactions
X.c - Capillary/vascular leak syndrome (CLS) (see also under Xr)
X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
X.j X - Systemic conditions, syndromes and reactions
X.j - Myositis/polymyositis/DPM/rhabdomyolysis/myopathy
X.k X - Systemic conditions, syndromes and reactions
X.k - Sarcoid-like, granulomatous thoracic and/or extrathoracic reaction
X.u X - Systemic conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
XI.n XI - Miscellaneous
XI.n - Neutropenia, agranulocytosis (w/wo infection/sepsis)
XV.a XV - Pulmonary pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib)
XV.c XV - Pulmonary pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.e XV - Pulmonary pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XV.f XV - Pulmonary pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.k XV - Pulmonary pathology
XV.k - Path: Desquamative interstitial pneumonia (DIP-pattern)
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
1

Methotrexate

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary opacities
I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.q I - Interstitial/parenchymal lung disease
I.q - Nodules in lung parenchyma (a.k.a. nodulosis)
I.v I - Interstitial/parenchymal lung disease
I.v - Subclinical changes in lung function/PFT
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD or pulmonary fibrosis (Hamman-Rich syndrome)
I.aa I - Interstitial/parenchymal lung disease
I.aa - Delayed ILD, -pneumonitis, -fibrosis
II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
IV.d IV - Airway involvement
IV.d - Cough (lone)
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
V.b V - Pleural and/or pericardial involvement
V.b - Eosinophilic pleural effusion
V.i V - Pleural and/or pericardial involvement
V.i - Pleuritis (may cause acute chest pain (see also under XIc)
V.n V - Pleural and/or pericardial involvement
V.n - Hemopericardium - Bloody pericardial effusion
V.s V - Pleural and/or pericardial involvement
V.s - Serositis - Polyserositis
VI.a VI - Pulmonary vasculopathy
VI.a - Pulmonary embolism - Venous thromboembolism
VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic)
VIII.a VIII - Upper, central, large airway involvement
VIII.a - Angioedema (may cause UAO & asphyxia)
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
X.k X - Systemic conditions, syndromes and reactions
X.k - Sarcoid-like, granulomatous thoracic and/or extrathoracic reaction
X.u X - Systemic conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
XI.b XI - Miscellaneous
XI.b - Chest pain (acute - subacute)
XI.c XI - Miscellaneous
XI.c - Pleuritic chest pain (see also under Vi)
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericarditis, pericardial effusion, tamponade
XIII.b XIII - Neoplastic conditions
XIII.b - Lymphoproliferative disease (pulmonary, endothoracic)
XIII.g XIII - Neoplastic conditions
XIII.g - Lymphomatoid granulomatosis (pulmonary, endothoracic)
XIII.k XIII - Neoplastic conditions
XIII.k - Lymphoproliferative disease (extrathoracic)
XV.a XV - Pulmonary pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib)
XV.c XV - Pulmonary pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.e XV - Pulmonary pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XV.f XV - Pulmonary pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.h XV - Pulmonary pathology
XV.h - Path: Fibrotic NSIP pattern
XV.i XV - Pulmonary pathology
XV.i - Path: Pneumocyte atypia (reactive epithelial cells)
XV.w XV - Pulmonary pathology
XV.w - Path: Pulmonary edema (see also II/IIa)
XV.bq XV - Pulmonary pathology
XV.bq - Path: Lymphoproliferative disease, endothoracic
XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass shadowing/opacities (GGO)
XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation
XVI.bc XVI - Imaging
XVI.bc - Imaging: Intrathoracic lymph node enlargement
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.d XVII - Infections & related conditions
XVII.d - Pneumocystis jiroveci pulmonary colonization
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous mycobacterial infection
XVII.q XVII - Infections & related conditions
XVII.q - Viral pneumonia
XIX.a XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
XIX.b XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.b - BAL: An excess proportion of neutrophils
XIX.c XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.c - BAL: An excess proportion of eosinophils
1

Nivolumab

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.f I - Interstitial/parenchymal lung disease
I.f - Acute fibrinous organizing pneumonia (AFOP)
I.ad I - Interstitial/parenchymal lung disease
I.ad - Radiation recall pneumonitis
I.aj I - Interstitial/parenchymal lung disease
I.aj - Shrinking lung syndrome
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
II.d II - Pulmonary edema - ARDS - Acute respiratory failure
II.d - Pulmonary edema, cardiogenic
IV.y IV - Airway involvement
IV.y - Eosinophilic airways disease/bronchiolitis
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericardial effusion (ANA unknown or negative)
IX.a IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.a - Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)
IX.d IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.d - Ventilatory depression-Hypoventilation (may cause ARF). See also XIe
IX.h IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.h - Dyspnea, unexplained otherwise
IX.r IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.r - Myasthenia gravis (may cause neuromuscular ARF)
IX.y IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.y - A flare or relapse of preexisting myasthenia gravis
X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
X.g X - Systemic conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways)
X.j X - Systemic conditions, syndromes and reactions
X.j - Myositis/polymyositis/DPM/rhabdomyolysis/myopathy
X.k X - Systemic conditions, syndromes and reactions
X.k - Sarcoid-like, granulomatous thoracic and/or extrathoracic reaction
X.u X - Systemic conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
X.ay X - Systemic conditions, syndromes and reactions
X.ay - Polymyalgia rheumatica
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericarditis, pericardial effusion, tamponade
XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis
XII.g XII - Cardiovascular involvement / toxicity
XII.g - Myocardial ischemia, coronary artery disease, myocardial infarction
XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-)
XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - Cardiotoxicity
XV.c XV - Pulmonary pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.d XV - Pulmonary pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)
XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating lung nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)
XVI.af XVI - Imaging
XVI.af - Imaging: Lung cysts or bullae (see also XVI ah/bf)
XVII.a XVII - Infections & related conditions
XVII.a - Pneumonia - Respiratory tract infection
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
XVII.aj XVII - Infections & related conditions
XVII.aj - Bordetella bronchiseptica pulmonary infection
1

Paraquat

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD or pulmonary fibrosis (Hamman-Rich syndrome)
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
II.c II - Pulmonary edema - ARDS - Acute respiratory failure
II.c - ARDS and the hemolytic-uremic syndrome (HUS)
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
IV.k IV - Airway involvement
IV.k - Bronchiectasis
X.u X - Systemic conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
XI.n XI - Miscellaneous
XI.n - Neutropenia, agranulocytosis (w/wo infection/sepsis)
XI.r XI - Miscellaneous
XI.r - Death following exposure or poisoning
XV.a XV - Pulmonary pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib)
XV.h XV - Pulmonary pathology
XV.h - Path: Fibrotic NSIP pattern
XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation
XVI.n XVI - Imaging
XVI.n - Imaging: Intralobular septal thickening - Crazy paving
XVI.q XVI - Imaging
XVI.q - Imaging: A pattern similar/consistent to/with IPF
1

Phenytoin (diphenylhydantoin)

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
III.b III - Pulmonary hemorrhage
III.b - Pneumorenal syndrome
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
IV.d IV - Airway involvement
IV.d - Cough (lone)
IV.n IV - Airway involvement
IV.n - Obstructive airway dysfunction (see also IVc)
VI.d VI - Pulmonary vasculopathy
VI.d - Pulmonary vasculitis or capillaritis
VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic)
VII.b VII - Mediastinal involvement
VII.b - Lymphadenopathy with reactive changes
VII.m VII - Mediastinal involvement
VII.m - Malignant lymphoma
X.a X - Systemic conditions, syndromes and reactions
X.a - DRESS (drug rash eosinophilia and hypersensitivity syndrome)
X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.h X - Systemic conditions, syndromes and reactions
X.h - Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
X.m X - Systemic conditions, syndromes and reactions
X.m - Pulmonary and/or systemic vasculitis (ANCA status MPO, unknown or negative)
X.u X - Systemic conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
XI.ab XI - Miscellaneous
XI.ab - Gingival hypertrophy
XII.m XII - Cardiovascular involvement / toxicity
XII.m - Cardiac/cardiopulmonary arrest
XII.x XII - Cardiovascular involvement / toxicity
XII.x - Sinus arrest
XIII.b XIII - Neoplastic conditions
XIII.b - Lymphoproliferative disease (pulmonary, endothoracic)
XIV.a XIV - Hemoglobinopathies-Abnormal hemoglobins states (acquired)
XIV.a - Methemoglobinemia
XV.m XV - Pulmonary pathology
XV.m - Path: Lymphoid hyperplasia - LIP-pattern
XV.ab XV - Pulmonary pathology
XV.ab - Path: Pulmonary capillaritis (see also IIIa, Xm, Xs)
XV.ac XV - Pulmonary pathology
XV.ac - Path: Pulmonary vasculitis other than capillaritis
XV.af XV - Pulmonary pathology
XV.af - Path: Granulomatous pulmonary vasculitis
XIX.a XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
1

Propofol

II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
II.f II - Pulmonary edema - ARDS - Acute respiratory failure
II.f - Hypoxemia, low saturation (may occur in isolation)
II.i II - Pulmonary edema - ARDS - Acute respiratory failure
II.i - Flash (fulminate) pulmonary edema
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
IV.b IV - Airway involvement
IV.b - Bronchospasm and angioedema
IV.d IV - Airway involvement
IV.d - Cough (lone)
IV.e IV - Airway involvement
IV.e - Cough (acute, violent, explosive)
IV.f IV - Airway involvement
IV.f - Severe, catastrophic asthma attack (can be fatal)
VI.e VI - Pulmonary vasculopathy
VI.e - Fat/oil embolism
VIII.h VIII - Upper, central, large airway involvement
VIII.h - Vocal cord dysfunction, adduction, closure
IX.d IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.d - Ventilatory depression-Hypoventilation (may cause ARF). See also XIe
IX.p IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.p - Disordered breathing during sleep
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
X.u X - Systemic conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
X.aa X - Systemic conditions, syndromes and reactions
X.aa - Propofol infusion syndrome (PRIS)
XI.d XI - Miscellaneous
XI.d - Metabolic acidosis (incl. lactic-). May cause dyspnea
XI.r XI - Miscellaneous
XI.r - Death following exposure or poisoning
XI.x XI - Miscellaneous
XI.x - Addictive risk
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left ventricular dysfunction/failure
XII.m XII - Cardiovascular involvement / toxicity
XII.m - Cardiac/cardiopulmonary arrest
XII.w XII - Cardiovascular involvement / toxicity
XII.w - Asystole
XV.ae XV - Pulmonary pathology
XV.ae - Path: Lipid/fat embolism (see also VIe)
1

Silicone (fluid)

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules
I.z I - Interstitial/parenchymal lung disease
I.z - Areas of consolidation
I.al I - Interstitial/parenchymal lung disease
I.al - Silicone pneumonitis - 'Silicone lung'
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
VI.m VI - Pulmonary vasculopathy
VI.m - Silicone embolism (SE) - SE syndrome
VII.k VII - Mediastinal involvement
VII.k - Mediastinal silicone infiltration
VIII.k VIII - Upper, central, large airway involvement
VIII.k - Submucosal airway petechiae/hemorrhage
X.u X - Systemic conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
XI.b XI - Miscellaneous
XI.b - Chest pain (acute - subacute)
XI.aa XI - Miscellaneous
XI.aa - CNS symptoms or involvement, stroke
XV.c XV - Pulmonary pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.g XV - Pulmonary pathology
XV.g - Path: Alveolar hemorrhage (see also IIIa)
XV.bn XV - Pulmonary pathology
XV.bn - Path: Silicone in lung tissue, pulmonary vasculature or pleura
XV.bo XV - Pulmonary pathology
XV.bo - Path: Siliconoma
XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass shadowing/opacities (GGO)
XVI.e XVI - Imaging
XVI.e - Imaging: Pulmonary opacities with a subpleural distribution
XVI.ax XVI - Imaging
XVI.ax - Imaging: Foreign body pulmonary embolism
XIX.d XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.d - BAL: Gross or microscopic bleeding/hemorrhage
XIX.l XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.l - BAL: Silicone globules in macrophages
1